'Venous Ultrasound' p3 Searchterm 'Venous Ultrasound' found in 21 articles 1 term [ • ] - 4 definitions [• ] - 16 booleans [• ]Result Pages : •
SonoGen (QW7437) is an anionically charged 2% perfluorocarbon emulsion under development as a transpulmonary myocardial ultrasound contrast agent (UCA). The SonoGen microbubbles have a reduced adherence to the negatively charged vascular endothelium and reduced coalescence. SonoGen, a second generation USCA has the theoretical potential to provide high safety and efficacy and improved tissue grayscale persistence compared to first generation fluorocarbon contrast agents.
Drug Information and Specification
RESEARCH NAME
DEVELOPER
INDICATION -
DEVELOPMENT STAGE Echocardiography - Phase 1
APPLICATION
Intravenous injection
TYPE
Microbubble
Surfactant
CHARGE
Negative
Dodecafluoropentane
MICROBUBBLE SIZE
-
PREPARATION
-
DO NOT RELY ON THE INFORMATION PROVIDED HERE, THEY ARE
NOT A SUBSTITUTE FOR THE ACCOMPANYING PACKAGE INSERT! •
The Doppler velocity signal refers to a signal whose voltage is proportional to the Doppler frequency shift, obtained by a frequency-to-voltage conversion of the Doppler signal. See also Autocorrelation, Temporal Mean Velocity, Doppler Effect, Doppler Ultrasound and Maximum Venous Outflow. •
The first generation ultrasound contrast agents (UCA/USCA) do not pass the pulmonary vascular bed, and are therefore limited to the venous system and the right heart cavities after intravenous injection.
•
The second generation ultrasound contrast agents (UCA/USCA) are both sufficiently small and stable to pass into the systemic circulation, and these contrast media enhance the Doppler signal in various arteries after intravenous injection. Second generation agents have a short live, the contrast effect is over in a few minutes.
•
Tissue-specific ultrasound contrast agents improve the image contrast resolution through differential uptake. The concentration of microbubble contrast agents within the vasculature, reticulo-endothelial, or lymphatic systems produces an effective passive targeting of these areas. Other contrast media concepts include targeted drug delivery via contrast microbubbles. Tissue-specific ultrasound contrast agents are injected intravenously and taken up by specific tissues or they adhere to specific targets such as venous thrombosis. These effects may require minutes to several hours to reach maximum effectiveness. By enhancing the acoustic differences between normal and diseased tissues, these tissue-specific agents improve the detectability of abnormalities. Some microbubbles accumulate in normal hepatic tissue; some are phagocytosed by Kupffer cells in the reticuloendothelial system and others may stay in the sinusoids. Liver tumors without normal Kupffer cells can be identified by the lack of the typical mosaic color pattern of the induced acoustic emission. The hepatic parenchymal phase, which may last from less than an hour to several days, depending on the specific contrast medium used, may be imaged by bubble-specific modes such as stimulated acoustic emission (color Doppler using high MI) or pulse inversion imaging. Further Reading: News & More:
Result Pages : |